1 hour ago
1
Upgrade to High-Speed Internet for only ₱1499/month!
Enjoy up to 100 Mbps fiber broadband, perfect for browsing, streaming, and gaming.
Visit Suniway.ph to learn
Years after Dengvaxia, the Philippines still carries scars that statistics alone cannot measure.
For much of the scientific community, the conversation has largely moved on. New vaccines have emerged. Regulatory frameworks have evolved. Lessons have been learned. Science, as it should, continues to advance.
Societies do not always move at the same speed.
That distinction matters because medicine is entering one of the most innovative periods in modern history. New therapies are emerging at a pace that would have been difficult to imagine even a decade ago.
One of the latest examples comes from pancreatic cancer, one of the deadliest forms of cancer known to medicine.
In May 2026, the New England Journal of Medicine published the Phase 3 RASolute 302 trial evaluating Daraxonrasib, a novel targeted therapy for patients with previously treated metastatic pancreatic cancer. The results were remarkable. Patients receiving Daraxonrasib achieved a median overall survival of 13.2 months compared with 6.7 months for those receiving standard chemotherapy. More than half of patients receiving Daraxonrasib were still alive after one year, compared with only 17% of those receiving chemotherapy. Tumor response rates nearly tripled, and patients were less likely to discontinue treatment because of side effects.
For a disease where progress has often been measured in small increments, these findings represent genuine hope.
But, for Filipinos, the most important question is not whether Daraxonrasib works. The question is whether the Philippines is prepared for what comes next. Because Daraxonrasib is not an isolated breakthrough.
Across medicine, innovation is accelerating. GLP-1 therapies are reshaping the management of obesity and diabetes. Antibody-drug conjugates are transforming cancer treatment. Cell therapies, gene therapies, liquid biopsies, and AI-assisted diagnostics are rapidly moving from research laboratories into clinical practice.
The next generation of medicine is already here. Yet innovation alone is not enough.
A therapy can be scientifically successful and still fail to improve population health if society does not trust the institutions responsible for evaluating and implementing it.
Dengvaxia as national trauma
This is where the Philippine experience with Dengvaxia remains relevant.
Dengvaxia was never simply about a vaccine. It became a national trauma. Public confidence in vaccination programs weakened. Public officials faced investigations. The controversy spilled far beyond dengue itself and contributed to broader skepticism toward public health institutions. Whether every public fear was scientifically justified is no longer the only issue.
The social consequences were real. Dengvaxia is no longer merely a clinical, epidemiological, or public health issue. It has become a political one.
The scientific debate may have evolved, but the political consequences remain. Regulators evaluating new vaccines today are not operating in a neutral environment. They are not simply weighing efficacy data, safety signals, and disease burden. They are also navigating institutional memory, public skepticism, media scrutiny, and the possibility that even scientifically defensible decisions may carry significant political consequences.
Whether fair or not, the political risks of being wrong can weigh just as heavily as the scientific risks.
This is a lesson that global public health organizations, development agencies, and pharmaceutical companies sometimes underestimate.
A vaccine, drug, diagnostic, or medical technology may demonstrate clear benefit in clinical trials. It may receive approval from respected regulators overseas. It may be endorsed by leading scientific societies.
Clinical success vs public acceptance
Yet implementation does not occur in a vacuum.
Communities evaluate new interventions not only through efficacy and safety data, but also through memory, trust, and lived experience.
The lesson of Dengvaxia is not that innovation should be feared.
The lesson is that trust cannot simply be assumed.
Global health organizations and pharmaceutical companies sometimes approach implementation as though strong clinical evidence should automatically translate into public acceptance. In reality, trust is earned locally, not imported alongside scientific data.
What works in Geneva, Washington, or London may still require a different conversation in Manila.
Consider pancreatic cancer.
According to GLOBOCAN 2022 estimates from the International Agency for Research on Cancer, approximately 4,000 Filipinos are diagnosed with pancreatic cancer each year, while nearly 4,000 die from the disease. Although pancreatic cancer ranks far lower in incidence than breast, lung, or colorectal cancer, it remains among the country’s leading causes of cancer mortality.
Few diseases demonstrate such a narrow gap between diagnosis and death. So, for these patients, delays matter.
Would the Philippines wait for much longer?
Yet even if Daraxonrasib receives approval in major global markets, Filipino patients may still wait years before routine access becomes available locally. Regulatory review, commercial partnerships, pricing negotiations, physician adoption, and reimbursement mechanisms all take time.
Under an optimistic scenario, Daraxonrasib could reach the Philippines within one to two years after approval in the United States. More realistically, access may take two to four years depending on regulatory priorities, commercial interest, pricing considerations, and the willingness of manufacturers to enter smaller markets.
Cost presents an additional challenge. Although official pricing has not yet been announced, comparable targeted oncology therapies often cost hundreds of thousands of dollars annually. Based on current market benchmarks, treatment costs could potentially exceed P8 million to P15 million per patient per year before any discounts, insurance coverage, or patient assistance programs.
Compassionate use programs may provide earlier access for a limited number of patients with advanced disease. But compassionate use is not a substitute for a health system capable of evaluating, financing, and delivering innovation at scale.
The challenge facing the Philippines is therefore not choosing between innovation and caution. It needs both.
Regulators must remain rigorous enough to protect patients, yet flexible enough to ensure that promising therapies do not arrive years after the rest of the world has already benefited from them.
Daraxonrasib will not be the last breakthrough to test this balance. New dengue vaccines, obesity treatments, gene therapies, cell therapies, and precision oncology tools are already arriving.
The question is no longer whether medical innovation will continue. It will.
The question is whether the Philippines can build enough trust to benefit from it. – Rappler.com
Dr. Jaemin Park is an adjunct professor at the University of the Philippines College of Public Health and works across Southeast Asia on healthcare financing, medical innovation, and public sector reform.
